Evidence map›Paper›PMID 33861770›Full record

ArticlePloS one2021

Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies.

Daniel P Wickland, Yingxue Ren, Jason P Sinnwell, Joseph S Reddy, Cyril Pottier, Vivekananda Sarangi, Minerva M Carrasquillo, Owen A Ross, Steven G Younkin, Nilüfer Ertekin-Taner and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Daniel P WicklandDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.
Yingxue RenDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.
Jason P SinnwellDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.
Joseph S ReddyDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.ORCID 0000-0002-1783-4453
Cyril PottierDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Vivekananda SarangiDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.
Minerva M CarrasquilloDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Steven G YounkinDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Nilüfer Ertekin-TanerDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Matthew E HudsonNational Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.
Liudmila Sergeevna MainzerNational Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.
Joanna M BiernackaDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, United States of America.
Yan W AsmannDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, United States of America.ORCID 0000-0002-8896-2647
Mayo Clinic in Florida · USUniversity of Illinois Urbana-Champaign · USWinnMed · US

Funding

Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, PETERS, METTE · 2013 to 2022
$24.6M
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in ADR01AG061796 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2018 to 2022
$5.7M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG061796NIA NIH HHS U01 AG046139
6 · The paper itself

Abstract

Genetic studies have shifted to sequencing-based rare variants discovery after decades of success in identifying common disease variants by Genome-Wide Association Studies using Single Nucleotide Polymorphism chips. Sequencing-based studies require large sample sizes for statistical power and therefore often inadvertently introduce batch effects because samples are typically collected, processed, and sequenced at multiple centers. Conventionally, batch effects are first detected and visualized using Principal Components Analysis and then controlled by including batch covariates in the disease association models. For sequencing-based genetic studies, because all variants included in the association analyses have passed sequencing-related quality control measures, this conventional approach treats every variant as equal and ignores the substantial differences still remaining in variant qualities and characteristics such as genotype quality scores, alternative allele fractions (fraction of reads supporting alternative allele at a variant position) and sequencing depths. In the Alzheimer's Disease Sequencing Project (ADSP) exome dataset of 9,904 cases and controls, we discovered hidden variant-level differences between sample batches of three sequencing centers and two exome capture kits. Although sequencing centers were included as a covariate in our association models, we observed differences at the variant level in genotype quality and alternative allele fraction between samples processed by different exome capture kits that significantly impacted both the confidence of variant detection and the identification of disease-associated variants. Furthermore, we found that a subset of top disease-risk variants came exclusively from samples processed by one exome capture kit that was more effective at capturing the alternative alleles compared to the other kit. Our findings highlight the importance of additional variant-level quality control for large sequencing-based genetic studies. More importantly, we demonstrate that automatically filtering out variants with batch differences may lead to false negatives if the batch discordances come largely from quality differences and if the batch-specific variants have better quality.

Indexed as

Genome-Wide Association StudyAllelesAlzheimer DiseaseApolipoproteins EDatabases, GeneticExomeFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHigh-Throughput Nucleotide SequencingHumansMaleMembrane Transport ProteinsMitochondrial Precursor Protein Import Complex ProteinsPolymorphism, Single NucleotideApolipoproteins EMembrane Transport ProteinsMitochondrial Precursor Protein Import Complex ProteinsTOMM40 protein, human

Identifiers

PMID33861770
PMCPMC8051815
OpenAlexW3152857445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.